Joseph Hulihan
Technik-/Wissenschafts-/F&E-Leiter bei MARINUS PHARMACEUTICALS, INC.
Vermögen: 17 619 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Joseph Hulihan
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 28 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Joseph Hulihan
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Director/Board Member Director/Board Member | |
| TREVENA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| POLYMEDIX, INC. | Pharmaceuticals: Major | Chief Executive Officer Investor Relations Contact | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Chairman Director/Board Member | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman General Counsel | |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor | |
National Investor Relations Institute
 National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| ALAUNOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Biotechnology | Chief Executive Officer General Counsel | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
Cnd Life Sciences, Inc.
 Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | Medical/Nursing Services | Director/Board Member | |
| The University of California, San Francisco | College/University | Doctorate Degree | |
| University of California, Berkeley | College/University | Doctorate Degree | |
| Dartmouth College | College/University | Undergraduate Degree | |
| PROTHENA CORPORATION PLC | Biotechnology | Chief Tech/Sci/R&D Officer | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Corporate Officer/Principal | |
| PROTAGONIST THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Hawaii Biotech, Inc.
 Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | Pharmaceuticals: Other | Director/Board Member | |
| METAGENOMI, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Biotechnology | Corporate Officer/Principal | |
| Worcester Polytechnic Institute | College/University | Undergraduate Degree | |
| University of Colorado Boulder | College/University | Doctorate Degree | |
| MOMENTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Universidad Autónoma de Madrid | College/University | Doctorate Degree | |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Miami VA Health Care System / Research | Corporate Officer/Principal | ||
| The University of Miami Leonard M. Miller School of Medicine | College/University | Corporate Officer/Principal | |
| Delaware Valley University | College/University | Undergraduate Degree | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Investor Relations Contact | |
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Miscellaneous Commercial Services | Founder | |
| Philadelphia University | College/University | Doctorate Degree | |
| Juniata College | College/University | Undergraduate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Pharmaceuticals: Major | General Counsel |
Statistik
International
| Vereinigte Staaten | 46 |
| Kanada | 3 |
| Irland | 2 |
| Spanien | 2 |
Sektoral
| Health Technology | 34 |
| Consumer Services | 12 |
| Commercial Services | 4 |
| Health Services | 2 |
Operativ
| Director/Board Member | 109 |
| Corporate Officer/Principal | 61 |
| Independent Dir/Board Member | 44 |
| Undergraduate Degree | 24 |
| Chief Tech/Sci/R&D Officer | 19 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Nicole Vitullo | 28 |
| Scott Braunstein | 25 |
| Michael Dougherty | 18 |
| Tim Mayleben | 18 |
| Seth Fischer | 17 |
| Sarah Noonberg | 17 |
| Elan Ezickson | 17 |
| Santiago Arroyo | 14 |
| Martha Manning | 13 |
| Sara Nochur | 11 |
| Edward Smith | 11 |
| Christine Silverstein | 10 |
| Lisa M. Caperelli | 9 |
| Enrique Carrazana | 9 |
| Steven Pfanstiel | 8 |
- Börse
- Insiders
- Joseph Hulihan
- Unternehmensverbindungen
